Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation

Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0074522. doi: 10.1128/aac.00745-22. Epub 2022 Sep 27.


Ceftaroline represents an attractive therapy option for methicillin-resistant Staphylococcus aureus (MRSA). Little data is available, however, regarding the frequency of reduced susceptibility (RS) to ceftaroline among pediatric MRSA infections. We screened invasive MRSA isolates at a tertiary children's hospital for ceftaroline RS. Ceftaroline RS occurred in 2.9% of isolates and only among health care associated infections. Ceftaroline RS isolates were more often clindamycin-resistant. Sequencing data indicated the predominance of the CC5 lineage among ceftaroline RS isolates.

Keywords: MRSA; ceftaroline; health care associated; invasive; mecR; pediatric; resistance.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Cephalosporins / pharmacology
  • Cephalosporins / therapeutic use
  • Child
  • Clindamycin
  • Genomics
  • Humans
  • Methicillin-Resistant Staphylococcus aureus* / genetics
  • Microbial Sensitivity Tests
  • Staphylococcal Infections* / drug therapy


  • T 91825
  • Clindamycin
  • Anti-Bacterial Agents
  • Cephalosporins